Navigation Links
Avicena's HD-02 to Proceed to NIH Sponsored Phase III Huntington's Disease Trial
Date:3/12/2008

tion results in a variety of symptoms including uncontrolled muscle movement, loss of intellectual capacity, and severe emotional disturbances.

Approximately 35,000 people in the US suffer from the symptoms of Huntington's disease and an additional 150,000 Americans are at risk to be carriers of the Huntington's gene. Carriers of the Huntington's gene will develop this deadly disease during their lifetime.

ABOUT AVICENA

Avicena Group, Inc. is a Palo Alto, California based late-stage biotechnology company that develops central nervous system therapeutics for neurodegenerative diseases. The Company's core technologies, supported by a robust IP portfolio, have broad applications in both pharmaceuticals and dermaceuticals. Avicena's pharmaceutical program centers on rare neurological disorders (orphan diseases). Near term, the Company plans to initiate a Phase III trial in Huntington's disease as discussed above and a confirmatory Phase III trial in ALS to accompany the ongoing NIH Phase III trial in Parkinson's disease. Avicena's science is well established and its products are safe and well tolerated. Unlike traditional biotechnology companies, Avicena's clinical programs are largely funded by government and non-profit organizations. Avicena presently derives revenue from the sale of proprietary dermaceutical ingredients to skin care manufacturers.

SAFE HARBOR

This release contains forward-looking statements that reflect, among other things, management's current expectations, plans and strategies, all of which are subject to known and unknown risks, uncertainties and factors that may cause our actual results to differ materially from those expressed or implied by these forward-looking statements. Many of these risks are beyond our ability to control or predict. See "Risk Factors" under "Item 6. Management's Discussion and Analysis of Financial Condition and Results of Operation" from our Annual Report on Form 10-KSB for the year ende
'/>"/>

SOURCE Avicena Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
2. Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial
3. Baxter to Proceed With Recall of Remaining Heparin Sodium Vial Products
4. Complete ANX-530 Safety Data to be Published in the 2008 Proceedings of the American Society of Clinical Oncology
5. CuraGen and TopoTarget Announce Initiation of an NCI-sponsored Phase II Clinical Trial of Belinostat for Thymoma and Thymic Carcinoma
6. Arizona Pain Society and Dr. Robert Barkin, Rush University Medical Center, Present Program on Comprehensive Urine Drug Testing Sponsored by Dominion Diagnostics
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
11. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... Seoul Semiconductor (CEO: Chung-hoon Lee, ... on May 28th announced that it will increase ... its high efficient and high reliable LED product ... Seoul Semiconductor has developed efficient and reliable LED ... supplied LEDs for headlamps to global auto makers. ...
(Date:5/28/2015)... , May 28, 2015  Quest Diagnostics Incorporated (NYSE: ... information services, announced that it is scheduled to speak ... York.  Steve Rusckowski , the company,s President and ... point strategy.  The presentation is scheduled for Tuesday, June ... The presentation will be webcast live during the conference ...
(Date:5/28/2015)... Research and Markets( http://www.researchandmarkets.com/research/6cg3zw/cell_therapy ) has ... "Cell Therapy - Technologies, Markets and Companies" ... describes and evaluates cell therapy technologies and methods, ... role in the practice of medicine. Hematopoietic stem ... marrow transplants. Role of cells in drug discovery ...
(Date:5/28/2015)... SAN CARLOS, Calif. , May 28, 2015 ... genetic testing, today announced a study published in ... that the Panorama single-nucleotide polymorphism (SNP)-based non-invasive prenatal ... in the first trimester. A ... indicates that complete molar pregnancies occur in about ...
Breaking Biology Technology:Seoul Semiconductor Increases the Global Automotive LED Market Share with its High Efficient and Reliable LEDs for Automotive Lightings 2Quest Diagnostics to Speak at the Jefferies 2015 Global Healthcare Conference 2Global Cell Therapy Market 2015-2020 - Technologies, Markets and Companies 2First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 2First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 3
... , Introduction , ... , or probes in genetic analysis. Quality control ... by slab gel electrophoresis or HPLC, but these , ... not provide desired quantitative precision or automation. Capillary electrophorsis , ...
... Michiels 1 , Baudouin Franois 1, 2 , and Jef , ... Centrum, Universitaire Campus, B-3590 Diepenbeek, Belgium , ... , Phenylketonuria (PKU) is a hereditary disease ... phenylalanine. The disease most frequently is caused by , ...
... Shiell and Wojtek P. Michalski, CSIRO Division of Animal Health,Australian Animal Health Laboratory, Geelong, ... Introduction , ... performed , on samples derived from polyacrylamide ... used method of recovering proteins from gels, can be , ...
Cached Biology Technology:Oligonucleotide Purity Analysis by Capillary Electrophoresis 2Oligonucleotide Purity Analysis by Capillary Electrophoresis 3Identification of Disease Causing Mutations in Phenylketonuria by Denaturing Gradient Gel Electrophoresis Using the DCode System 2Identification of Disease Causing Mutations in Phenylketonuria by Denaturing Gradient Gel Electrophoresis Using the DCode System 3Identification of Disease Causing Mutations in Phenylketonuria by Denaturing Gradient Gel Electrophoresis Using the DCode System 4Identification of Disease Causing Mutations in Phenylketonuria by Denaturing Gradient Gel Electrophoresis Using the DCode System 5Fractionation of Bovicola ovis Homogenates Using the Mini Whole Gel Eluter 2Fractionation of Bovicola ovis Homogenates Using the Mini Whole Gel Eluter 3
(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
(Date:5/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, reminds investors and media that  Mr. ...  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series of nine ... Global Fraud: Where is the Trust in Cyberspace? ...
(Date:4/20/2015)... April 20, 2015 Huntington Memorial Hospital is ... implant a new miniaturized, wireless monitoring sensor to manage ... first and only FDA-approved heart failure monitoring device that ... used by physicians to manage heart failure. ... implanted in the pulmonary artery (PA) during a non-surgical ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... native fish in Australia,s Murray-Darling Basin may be linked ... This is just one of the findings from a ... back into the Murray-Darling system limit fish reproduction and ... Rob Rolls said the results, published in Freshwater ...
... disorder characterized by the breakdown of cognition processes and ... throughout history. Scientists believe that several genes are associated ... single gene causes the disease by itself. It is ... necessary for schizophrenia to develop and that epigenetic change ...
... weapons testing of the 1950s and ,60s, Lawrence Livermore ... human brain involved in memory makes new neurons well ... on human behavior and mental health. The study supports ... adult neurogenesis to the treatment of age-related cognitive disorders. ...
Cached Biology News:Weapons testing data determines brain makes new neurons into adulthood 2
Phospho- (Ser/Thr) PDK1 Docking Motif (18A2) Mouse mAb...
... clone 41D GenBank Accession Number ... clusterin purified from human serum Formulation: ... and 0.05% sodium azide Quality Assurance: ... HeLa cells or MCF-7 cell lysates. ...
Anti-MT3-MMP Membrane-Type Metalloproteinase-3; propeptide domain; rabbit host...
Rabbit polyclonal to Methionine Aminopeptidase 2 ( Abpromise for all tested applications). entrezGeneID: 10988 SwissProtID: P50579...
Biology Products: